Overview

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Genexine, Inc.
Treatments:
Bevacizumab